FinancialContent is the trusted provider of stock market information to the media industry
Aeterna Zentaris Granted Special Protocol Assessment
Posted on December 28, 2012 at 16:53 PM EST
The Food and Drug Administration granted Aeterna Zentaris Inc. (Nasdaq: AEZS) Special Protocol Assessment for a Phase 3 registration trial of its endometrial cancer treatment AEZS-108 lifting the stock price 3 cents to close at $2.47.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here